Exelixis
EXEL
#1571
Rank
โ‚น941.26 B
Marketcap
โ‚น3,363
Share price
-0.36%
Change (1 day)
80.02%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

EPS for Exelixis (EXEL)

EPS in 2023 (TTM): โ‚น23.20

According to Exelixis's latest financial reports the company's current EPS (TTM) is โ‚น24.72. In 2022 the company made an earnings per share (EPS) of โ‚น49.73 a decrease over its 2021 EPS that were of โ‚น64.56.

EPS history for Exelixis from 2000 to 2023

Annual EPS

Year EPS Change
2023 (TTM)โ‚น23.20-53.35%
2022โ‚น49.73-22.97%
2021โ‚น64.56100%
2020โ‚น32.28-65.09%
2019โ‚น92.47-53.91%
2018โ‚น200.65333.96%
2017โ‚น46.24-260.61%
2016-โ‚น28.79-58.75%
2015-โ‚น69.79-42.45%
2014-โ‚น121.265.3%
2013-โ‚น115.1643.48%
2012-โ‚น80.26-264.29%
2011โ‚น48.85-165.88%
2010-โ‚น74.15-32.54%
2009-โ‚น109.92-17.65%
2008-โ‚น133.4875.86%
2007-โ‚น75.90-25.64%
2006-โ‚น102.078.33%
2005-โ‚น94.22-42.86%
2004-โ‚น164.8830.34%
2003-โ‚น126.50-5.23%
2002-โ‚น133.48-0.65%
2001-โ‚น134.35-51.88%
2000-โ‚น279.17

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
โ‚น305.40 1,135.69%๐Ÿ‡ฌ๐Ÿ‡ง UK
โ‚น277.45 1,022.57%๐Ÿ‡ซ๐Ÿ‡ท France
โ‚น158.92 543.02%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚น346.34 1,301.34%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚น1,234 4,894.71%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚น1,229 4,871.87%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚น162.27 556.55%๐Ÿ‡บ๐Ÿ‡ธ USA
-โ‚น872.40-3,629.83%๐Ÿ‡บ๐Ÿ‡ธ USA
-โ‚น73.28-396.51%๐Ÿ‡บ๐Ÿ‡ธ USA